Italia markets close in 8 hours 19 minutes
FTSE MIB
33.987,67 -118,33 (-0,35%) Dow Jones
39.375,87 +67,87 (+0,17%) Nasdaq
18.352,76 +164,46 (+0,90%) Nikkei 225
40.780,70 -131,67 (-0,32%) Petrolio
82,67 -0,49 (-0,59%) Bitcoin EUR
51.384,81 -1.837,63 (-3,45%)
Illumina Inc (ILU.HA)
Hanover - Hanover Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
In data: 08:01AM CEST. Mercato aperto.
| Chiusura precedente | 96,48 |
| Aperto | 99,26 |
| Denaro | 99,27 x N/D |
| Domanda | 100,76 x N/D |
| Min-Max giorno | 99,26 - 99,26 |
| Intervallo di 52 settimane | 85,60 - 173,78 |
| Volume | |
| Media Volume | 7 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
© 2024 Yahoo. Tutti i diritti riservati.